Home
/ Navigen
/ Competitors

Navigen Competitors and Similar CompaniesClear all

Navigen's competitors and similar companies include AVEO Pharmaceuticals, Signpath Pharma, NanoCarrier and Active Biotech.

	Navigen Navigen is a pharmaceutical discovery and development company.	AVEO Pharmaceuticals AVEO is a biopharmaceutical company focused on the discovery and development of targeted cancer therapeutics.	Signpath Pharma SignPath Pharma is a biotechnology company that develops products to treat cancer and mitigate drug-induced cardiac arrhythmia.	NanoCarrier NanoCarrier (ナノキャリア株式会社) is a company engaged in the research and development of pharmaceuticals using micellar nanoparticle technology.	Active Biotech Active Biotech is a biotechnology company with a focus on neurodegenerative and inflammatory diseases and cancer.
Founding Date	Founding Date 2006	Founding Date 2001	Founding Date 2006	Founding Date 1996	Founding Date 1998
Type	Type Private	Type Public	Type Private	Type Public	Type Public
Tags	Tags Healthcare drug development oncology pharma	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development oncology pharma
Locations	Locations Salt Lake City, US HQ	Locations Boston, US HQ	Locations Sandy, US HQ	Locations 柏市, JP HQ Chuo City, JP	Locations Lund, SE HQ Lund, SE
Employees	Employees 13	Employees 1912% increase	Employees 11	Employees 18	Employees 517% decrease
Valuation ($)	Valuation ($) N/A	Valuation ($) 515.6 m	Valuation ($) N/A	Valuation ($) 78 m	Valuation ($) 21 m
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) $42.3m (FY, 2021)	Revenue (est.) N/A	Revenue (est.) ¥108.5m (FY, 2025)	Revenue (est.) N/A
Cost of goods	Cost of goods N/A	Cost of goods $4.7m (FY, 2021)	Cost of goods N/A	Cost of goods ¥30.3m (FY, 2025)	Cost of goods N/A
Gross profit	Gross profit N/A	Gross profit N/A	Gross profit N/A	Gross profit ¥78.2m (FY, 2025)	Gross profit N/A
Net income	Net income N/A	Net income ($53.3m) (FY, 2021)	Net income N/A	Net income (¥835.4m) (FY, 2025)	Net income (kr37.3m) (FY, 2025)
Funding
Total funding raised	Total funding raised $ 1.7m	Total funding raised $ 224m	Total funding raised $ 5.3m	Total funding raised N/A	Total funding raised N/A